Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Pianoboost a hit on Google Play Store
2017-03-01

Description: Pianoboost Tags: Pianoboost

Pianoboost is an interactive app developed by
Dr Frelet de Villiers, lecturer in the Odeion School of Music
at the University of the Free State.
Photo: Supplied

“I got the idea after watching my children play Sing Star on PlayStation, where the game can detect how accurately you sing. I realised this could turn my dream into a reality if I looking into the possibility of an app that can do note recognising,” says Dr Frelet de Villiers, developer of the Pianoboost app, about her brainchild.

Dr De Villiers, lecturer in the Odeion School of Music (OSM) at the University of the Free State (UFS), developed this interactive app for piano learners to learn music. She started the developing process three years ago, but the project only got momentum when she  approached LivX, a digital developing company in Pretoria, six months ago.

Useful for other instruments
Pianoboost has been live since 9 February 2017 and already received positive reviews, with a five-star rating on the Google Play Store. “In my experience as piano teacher, I know that learners struggle to learn their notes. They can’t recognise the note on the music sheet and therefore cannot play it on the piano,” says Dr De Villiers. Although this app is developed for piano, it is also successfully used for other instruments like the marimba, violin, and guitar, because it can pick up sounds from almost any instrument.

Ideal for use in academic programme
There are students in the certificate and diploma modules at the OSM who haven’t received any formal music training. Therefore, the app is ideal for them to use. “We have instrument-specific methodology in our degree courses. So, those students could also be exposed to the app for use in their own teaching of young learners,” says Dr De Villiers.

Different features sets app apart
The app, available on Android devices, has instant music recognition and impressive features that already sets it apart from existing learning apps. It is used on a real acoustical piano (you do not need to plug the tablet into a keyboard), has instant note recognition, shows the correct position of the note on the piano when you are wrong, and works like a flash card system, to name a few. “By using the app, you also learn the names of notes whether you played it right or wrong,” says Dr De Villiers.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept